Inclusion Criteria:

- Males or females with a suspected or histologically confirmed index oral premalignant
lesion (excluding carcinoma in situ), 12mm or greater in size that has not been
biopsied in the past 6 weeks; each index lesion must be either a:

- dysplastic measurable leukoplakia or erythroplakia in the oral cavity or
accessible oropharynx, or

- hyperplastic leukoplakia of high-risk sites, lateral and ventral tongue and
floor of mouth

- The subject's life expectancy is > 12 weeks and Karnofsky performance score is
70-100%

- Hemoglobin and hematocrit levels above the lower limit of normal

- White blood cells >= 3,000/uL

- Platelets >= 125,000/uL

- Total bilirubin =< 1.5 x ULN

- AST (SGOT)/ALT (SGPT) =< 1.5 x ULN

- BUN and serum creatinine =< 1.5 x ULN

- LDH =< 1.5 x ULN

- If the subject is female and of childbearing potential (women are considered not of
childbearing potential if they are at least two years postmenopausal and/or
surgically sterile), she:

- has been using adequate contraception (abstinence, IUD, birth control pills, or
spermicidal gel with diaphragm or condom) since her last menses and will use
adequate contraception during the study, AND

- is not lactating, AND

- has a documented negative serum pregnancy test within 14 days prior to
randomization

- The subject has discontinued any other oral cancer chemopreventive therapy at least
12 weeks prior to the Baseline visit and all toxicities have been fully resolved;
daily aspirin is permitted

- The subject is willing and able to fully participate for the duration of the study

- If applicable, the subject has been counseled on smoking cessation

- The effects of rosiglitazone (Avandia) on the developing human fetus at the
recommended therapeutic dose are unknown; for this reason, and because rosiglitazone
has been associated with fetal death and growth retardation in rats and rabbits and
placental pathology in rats, women of child-bearing potential must agree to use
adequate contraception (hormonal or barrier method of birth control; abstinence)
prior to study entry and for the duration of study participation; should a woman
become pregnant or suspect she is pregnant while participating in this study, she
should inform her study physician immediately and will be removed from the trial

- Ability to understand and the willingness to sign a written informed consent document

- The subject is of New York Heart Association (NYHA) Class 1 to 4 cardiac status

Exclusion Criteria:

- The subject has active cancer or carcinoma in situ of the head and neck

- The subject has a contraindication to biopsy

- The subject has any history of congestive heart failure, any history of myocardial
infarction, angina, or coronary artery disease within the past 6 months, or active
cardiac disease

- The subject exhibits clinical evidence of active liver disease, history of chronic
liver disease or edema

- The subject currently receives insulin, sulfonylurea or metformin (doses of
rosiglitazone greater than 4 mg daily in combination with these therapies are not
currently indicated; because this protocol uses the maximum recommended dose of 8 mg
daily, subjects on insulin, sulfonylurea or metformin will be ineligible for
participation in this trial); the subject is currently receiving thiazolidinediones;
the subject is a diabetic not on treatment or hyperglycemic (has a random blood
glucose level > 200 mg/dl); the subject has diabetic macular edema

- The subject is currently receiving medical therapy for dysregulated blood sugar

- The subject has experienced jaundice with Rezulin® (troglitazone)

- The subject has known hypersensitivity to rosiglitazone, Avandia, or any of its
components

- The subject has a history of colorectal cancer, familial adenomatous polyposis (FAP)
or hereditary non-polyposis colorectal cancer (HNPCC)

- The subject has a history of invasive cancer within the past 18 months (excluding
non-invasive bladder cancer, non-melanoma skin cancer and in situ cervical cancer);
subjects (excluding those with a history of colorectal cancer, FAP or HNPCC) who
received curative treatment and have shown no evidence of recurrence for 18 months
will be eligible

- The subject has had chemotherapy, immunotherapy, hormonal therapy (other than HRT for
menopause), or radiation therapy within 18 months of the Baseline visit

- The subject will need concurrent chemotherapy, radiotherapy, hormonal (other than HRT
for menopause), or immunotherapy during the time of study

- The subject has received any investigational medication within 30 days of the
Baseline visit or is scheduled to receive an investigational drug during the course
of the study

- The subject participated in the study previously and was withdrawn

- The subject is pregnant or nursing

- Subjects who have had the study drug prior to this study

- The subject has uncontrolled intercurrent illness including: ongoing or active
infection, HIV, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements